Get the Stockscreener App
112.22
0.57%
0.625
Insmed Inc stock is traded at $112.22, with a volume of 1.09M.
It is up +0.57% in the last 24 hours and up +19.13% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$111.60
Open:
$110.6
24h Volume:
1.09M
Relative Volume:
0.30
Market Cap:
$24.33B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-19.54
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
+7.16%
1M Performance:
+19.13%
6M Performance:
-35.89%
1Y Performance:
+14.76%
1-Day Range:
$108.55
$112.57
1-Week Range:
$104.64
$112.57
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
112.24 | 23.11B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
528.45 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
648.65 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.87 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.73 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.38 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Here’s Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM) - Yahoo Finance
Analysts Expect Breakeven For Insmed Incorporated (NASDAQ:INSM) Before Long - Moomoo
INSMInsmed Inc Options - Finviz
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Incorporated(NasdaqGS:INSM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Insmed Incorporated(NasdaqGS: INSM) dropped from Russell Midcap Value Benchmark - marketscreener.com
Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM) - Yahoo Finance
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insmed Insider Sold Shares Worth $2,210,763, According to a Recent SEC Filing - marketscreener.com
INSMED (INSM) CEO Lewis exercises options and sells 21,398 shares under 10b5-1 plan - Stock Titan
Price to earnings forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Form 144 INSMED INC For: 25 June - Investing.com UK
Form 144 INSMED INC For: 25 June By Investing.com - Investing.com Nigeria
Insmed Incorporated Actuals & Estimates (NASDAQ:INSM) - TradingView
Insmed Incorporated Actuals & Estimates (BX:IM8N) - TradingView
William Lewis files Form 144 — Insmed (NASDAQ: INSM) reports recent share dispositions - Stock Titan
Insmed | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Enterprise value to EBITDA forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Price to sales forward of Insmed Incorporated – NASDAQ:INSM - TradingView
Enterprise value to EBIT forward of Insmed Incorporated – SWB:IM8N - TradingView
Price to book forward of Insmed Incorporated – SWB:IM8N - TradingView
Enterprise value to revenue forward of Insmed Incorporated – SWB:IM8N - TradingView
IM8N Forecast — Price Target — Prediction for 2027 - TradingView
Insmed names Butera SVP, general manager, global respiratory - ROI-NJ
Enterprise value to EBITDA forward of Insmed Incorporated – SWB:IM8N - TradingView
Non-Cystic Fibrosis Bronchiectasis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmace - Barchart.com
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis - Yahoo Finance
Form 4 Insmed Inc For: 24 June By Investing.com - Investing.com Australia
Insmed chief legal officer Michael Smith sells $173,050 in stock By Investing.com - Investing.com South Africa
Insmed chief legal officer Michael Smith sells $173,050 in stock - Investing.com
Insider Sell Alert: Michael Smith Sells Shares of Insmed Inc (IN - GuruFocus
Insmed (NASDAQ: INSM) awards RSUs and stock options to SVP - Stock Titan
Insmed (INSM) SVP Samuele Butera files Form 3 showing no trades - Stock Titan
INSMED Inc (NASDAQ: INSM) CLO sells 1,806 shares under 10b5-1 plan - Stock Titan
Insmed Incorporated Announces Appointment of Samuele Butera as Senior Vice President, Global Respiratory and Member of Executive Committee, Effective June 23, 2026 - marketscreener.com
Press Release: Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory - Moomoo
Form 144 INSMED INC For: 22 June By Investing.com - Investing.com Australia
INSM Maintained by Evercore ISI Group -- Price Target Lowered to $160 - GuruFocus
Insmed taps Johnson & Johnson veteran to lead its respiratory push - Stock Titan
Form 144 INSMED INC For: 22 June - Investing.com UK
Should Insmed’s (INSM) NASDAQ-100 Exit and TPIP Focus Require Action From Investors? - Yahoo Finance
Michael Smith files Form 144 listing multiple INSM share sales (INSM) - Stock Titan
Is Insmed (INSM) One of the Most Promising Healthcare Stocks After Cantor Fitzgerald’s Target Raise? - Yahoo Finance
What's Driving Insmed's Recent Volatility - Kavout | AI
3 US Pharmaceutical Stocks With Cash Flow And Pricing Risk - Sahm
Insmed Stockanalyst coverage and sector comparison at week’s end - Ad-hoc-news.de
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Jun 25 '26 |
Sale |
103.32 |
21,398 |
2,210,763 |
258,917 |
0.17%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):